NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis $54.38 -1.01 (-1.82%) Closing price 04:00 PM EasternExtended Trading$54.91 +0.53 (+0.98%) As of 05:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioMarin Pharmaceutical Stock (NASDAQ:BMRN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BMRN alerts:Sign Up Key Stats Today's Range$53.93▼$55.6650-Day Range$54.79▼$70.2452-Week Range$49.26▼$70.98Volume2.66 million shsAverage Volume2.08 million shsMarket Capitalization$10.53 billionP/E Ratio146.97Dividend YieldN/APrice Target$88.74Consensus RatingModerate Buy Company Overview BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy. Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates. BioMarin has also developed Roctavian, a gene therapy for adults with severe hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets. The company sells its therapies through specialty healthcare and commercial distribution networks and continues to invest in treatments for rare diseases. Alexander Hardy has served as BioMarin’s president and chief executive officer since 2023.AI Generated. May Contain Errors. Read More BioMarin Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreBMRN MarketRank™: 4.260526315785 of 5 starsBioMarin Pharmaceutical scored higher than 85% of companies evaluated by MarketBeat, and ranked 71st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 2 strong buy ratings, 14 buy ratings, 7 hold ratings, and 1 sell rating.Upside PotentialBioMarin Pharmaceutical has a consensus price target of $88.74, representing about 63.2% upside from its current price of $54.38.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioMarin Pharmaceutical's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth32.20% Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 32.20% in the coming year, from $4.10 to $5.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 146.97, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.94.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 146.97, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.75.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 0.39. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about BioMarin Pharmaceutical's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.99% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 5.51.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 14.36%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.35 News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for BioMarin Pharmaceutical this week, compared to 8 articles on an average week.Search Interest18 people have searched for BMRN on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by Insiders0.68% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BioMarin Pharmaceutical's insider trading history. Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMRN Stock News HeadlinesBank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)October 10 at 12:45 PM | theglobeandmail.comRBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)October 10 at 12:45 PM | theglobeandmail.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 13 at 1:00 AM | Base Camp Trading (Ad)Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT) and BioMarin Pharmaceutical (BMRN)October 9, 2026 | theglobeandmail.comBioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual MeetingOctober 9, 2026 | prnewswire.comBioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention?October 8, 2026 | finance.yahoo.comBioMarin Appoints Cara Bauer as Chief People OfficerOctober 5, 2026 | prnewswire.comBioMarin Pharmaceutical consensus price target increases 11.35% to MX$1,755.39October 3, 2026 | msn.comSee More Headlines BMRN Stock Analysis - Frequently Asked Questions How have BMRN shares performed this year? BioMarin Pharmaceutical's stock was trading at $59.43 at the beginning of the year. Since then, BMRN stock has decreased by 8.5% and is now trading at $54.38. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released its quarterly earnings results on Thursday, August, 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical's revenue was up 20.0% on a year-over-year basis. Read the conference call transcript. Who are BioMarin Pharmaceutical's major shareholders? Top institutional investors of BioMarin Pharmaceutical include First Financial Bank Trust Division (0.02%), Everhart Financial Group Inc., Farther Finance Advisors LLC and Miller Global Investments LLC. Insiders that own company stock include Jean Jacques Bienaime, Henry J Fuchs, Jeffrey Robert Ajer, Charles Greg Guyer, Brian Mueller, George Eric Davis, Gregory R Friberg, Cristin Hubbard and Erin Burkhart. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioMarin Pharmaceutical investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Salesforce (CRM), Vertex Pharmaceuticals (VRTX) and Regeneron Pharmaceuticals (REGN). Company Calendar Last Earnings8/06/2026Today10/13/2026Next Earnings (Estimated)10/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, BMRN's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CIK1048477 Webwww.biomarin.com Phone(415) 506-6700Fax415-382-7889Employees3,221Year Founded1997Price Target and Rating Average Price Target for BioMarin Pharmaceutical$88.74 High Price Target$124.00 Low Price Target$60.00 Potential Upside/Downside+63.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$0.37 Trailing P/E Ratio146.97 Forward P/E Ratio13.26 P/E Growth0.39Net Income$348.90 million Net Margins2.14% Pretax Margin4.38% Return on Equity5.32% Return on Assets3.69% Debt Debt-to-Equity Ratio0.56 Current Ratio2.39 Quick Ratio1.32 Sales & Book Value Annual Sales$3.22 billion Price / Sales3.27 Cash Flow$2.83 per share Price / Cash Flow19.20 Book Value$31.68 per share Price / Book1.72Miscellaneous Outstanding Shares193,570,000Free Float192,258,000Market Cap$10.53 billion OptionableOptionable Beta0.22 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BMRN) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersAI Microcap Teams With Gentex on Next-Gen Military HelmetsMorgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion...Capital Trends | SponsoredPalantir Micron and SanDisk surged before anyone noticedPalantir, Micron, and SanDisk show how fast a stock can move from overlooked to impossible to ignore. A new...StockEarnings | SponsoredFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | SponsoredHistory Shows Uranium Rallies Followed Major Convergence EventsUranium prices rose more than sevenfold after October 1973, then fourteenfold following October 2006, with som...Digest Publishing | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredTomorrow morning's stock alertOur research analysts are set to release their next stock idea tomorrow morning just before 12:00 PM Eastern. ...The Early Bird | SponsoredElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
